All In Biotech

Investigational drug · Phase 2

IBR854

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Renal Cell Carcinoma (RCC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "IBR854"

First trial start

2025

Sep 8, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "IBR854", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Renal Cell Carcinoma (RCC)

Approved drugs for the same conditions: Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "IBR854" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Renal Cell Carcinoma (RCC)

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • AL8326Phase 34 trials

    Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

  • GI-102Phase 22 trials

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)

  • GI-108Phase 21 trial

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC)

  • VMD-102Single agentPhase 21 trial

    VM Discovery, Inc. · Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.